text:
Label: CAPTOPRIL tablet
Contains inactivated NDC Code(s)
NDC Code(s): 53808-0217-1, 53808-0359-1
- Packager: DOH CENTRAL PHARMACY
- This is a repackaged label.
- Source NDC Code(s): 0143-1173, 0143-1174
- Category: HUMAN PRESCRIPTION DRUG LABEL
Drug Label Information
Updated January 23, 2017
If you are a healthcare professional or from the pharmaceutical industry please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
(What is this?)
When used in pregnancy during the second and third trimester, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, captopril should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
Captopril is a specific competitive inhibitor of angiotensin I-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I to angiotensin II.
Captopril is designated chemically as 1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline and has the following structural formula:
Captopril is a white to off-white crystalline powder that may have a slight sulfurous odor; it is soluble in water (approx. 160 mg/mL), methanol, and ethanol and sparingly soluble in chloroform and ethyl acetate.
Each tablet, for oral administration, contains 12.5 mg, 25 mg, 50 mg, or 100 mg of captopril. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, microcrystalline cellulose, sodium starch glycolate, starch, and stearic acid.
Mechanism of Action
The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. Angiotensin I is then converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the adrenal cortex, thereby contributing to sodium and fluid retention.
Captopril prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase. This inhibition has been demonstrated in both healthy human subjects and in animals by showing that the elevation of blood pressure caused by exogenously administered angiotensin I was attenuated or abolished by captopril. In animal studies, captopril did not alter the pressor responses to a number of other agents, including angiotensin II and norepinephrine, indicating specificity of action.
ACE is identical to "bradykininase," and captopril may also interfere with the degradation of the vasodepressor peptide, bradykinin. Increased concentrations of bradykinin or prostaglandin E2 may also have a role in the therapeutic effect of captopril.
Inhibition of ACE results in decreased plasma angiotensin II and increased plasma renin activity (PRA), the latter resulting from loss of negative feedback on renin release caused by reduction in angiotensin II. The reduction of angiotensin II leads to decreased aldosterone secretion, and, as a result, small increases in serum potassium may occur along with sodium and fluid loss.
The antihypertensive effects persist for a longer period of time than does demonstrable inhibition of circulating ACE. It is not known whether the ACE present in vascular endothelium is inhibited longer than the ACE in circulating blood.
After oral administration of therapeutic doses of captopril, rapid absorption occurs with peak blood levels at about one hour. The presence of food in the gastrointestinal tract reduces absorption by about 30 to 40 percent; captopril therefore should be given one hour before meals. Based on carbon-14 labeling, average minimal absorption is approximately 75 percent. In a 24-hour period, over 95 percent of the absorbed dose is eliminated in the urine; 40 to 50 percent is unchanged drug; most of the remainder is the disulfide dimer of captopril and captopril-cysteine disulfide.
Approximately 25 to 30 percent of the circulating drug is bound to plasma proteins. The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours. An accurate determination of half-life of unchanged captopril is not, at present, possible, but it is probably less than 2 hours. In patients with renal impairment, however, retention of captopril occurs (see DOSAGE AND ADMINISTRATION).
Administration of captopril results in a reduction of peripheral arterial resistance in hypertensive patients with either no change, or an increase in cardiac output. There is an increase in renal blood flow following administration of captopril and glomerular filtration rate is usually unchanged.
Reductions of blood pressure are usually maximal 60 to 90 minutes after oral administration of an individual dose of captopril. The duration of effect is dose related. The reduction in blood pressure may be progressive, so to achieve maximal therapeutic effects, several weeks of therapy may be required. The blood pressure lowering effects of captopril and thiazide-type diuretics are additive. In contrast, captopril and beta-blockers have a less than additive effect.
Blood pressure is lowered to about the same extent in both standing and supine positions. Orthostatic effects and tachycardia are infrequent but may occur in volume-depleted patients. Abrupt withdrawal of captopril has not been associated with a rapid increase in blood pressure.
In patients with heart failure, significantly decreased peripheral (systemic vascular) resistance and blood pressure (afterload), reduced pulmonary capillary wedge pressure (preload) and pulmonary vascular resistance, increased cardiac output, and increased exercise tolerance time (ETT) have been demonstrated. These hemodynamic and clinical effects occur after the first dose and appear to persist for the duration of therapy. Placebo controlled studies of 12 week duration in patients who did not respond adequately to diuretics and digitalis show no tolerance to beneficial effects on ETT; open studies, with exposure up to 18 months in some cases, also indicate that ETT benefit is maintained. Clinical improvement has been observed in some patients where acute hemodynamic effects were minimal.
The Survival and Ventricular Enlargement (SAVE) study was a multicenter, randomized, double-blind, placebo-controlled trial conducted in 2,231 patients (age 21-79 years) who survived the acute phase of myocardial infarction and did not have active ischemia. Patients had left ventricular dysfunction (LVD), defined as a resting left ventricular ejection fraction ≤40%, but at the time of randomization were not sufficiently symptomatic to require ACE inhibitor therapy for heart failure. About half of the patients had had symptoms of heart failure in the past. Patients were given a test dose of 6.25 mg oral captopril and were randomized within 3-16 days post-infarction to receive either captopril or placebo in addition to conventional therapy. Captopril was initiated at 6.25 mg or 12.5 mg t.i.d. and after two weeks titrated to a target maintenance dose of 50 mg tid. About 80% of patients were receiving the target dose at the end of the study. Patients were followed for a minimum of two years and for up to five years, with an average follow-up of 3.5 years.
Baseline blood pressure was 113/70 mmHg and 112/70 mmHg for the placebo and captopril groups, respectively. Blood pressure increased slightly in both treatment groups during the study and was somewhat lower in the captopril group (119/74 vs. 125/77 mmHg at 1 yr).
Therapy with captopril improved long-term survival and clinical outcomes compared to placebo. The risk reduction for all cause mortality was 19% (P=0.02) and for cardiovascular death was 21% (P=0.014). Captopril treated subjects had 22% (P=0.034) fewer first hospitalizations for heart failure. Compared to placebo, 22% fewer patients receiving captopril developed symptoms of overt heart failure. There was no significant difference between groups in total hospitalizations for all cause (2056 placebo; 2036 captopril).
Captopril was well tolerated in the presence of other therapies such as aspirin, beta blockers, nitrates, vasodilators, calcium antagonists and diuretics.
In a multicenter, double-blind, placebo controlled trial, 409 patients, age 18-49 of either gender, with or without hypertension, with type I (juvenile type, onset before age 30) insulin-dependent diabetes mellitus, retinopathy, proteinuria ≥500 mg per day and serum creatinine ≤2.5 mg/dL, were randomized to placebo or captopril (25 mg t.i.d.) and followed for up to 4.8 years (median 3 years). To achieve blood pressure control, additional antihypertensive agents (diuretics, beta blockers, centrally acting agents or vasodilators) were added as needed for patients in both groups.
The captopril group had a 51% reduction in risk of doubling of serum creatinine (P<0.01) and a 51% reduction in risk for the combined endpoint of end-stage renal disease (dialysis or transplantation) or death (P<0.01). Captopril treatment resulted in a 30% reduction in urine protein excretion within the first 3 months (P<0.05), which was maintained throughout the trial. The captopril group had somewhat better blood pressure control than the placebo group, but the effect of captopril on renal function were greater than would be expected from the group differences in blood pressure reduction alone. Captopril was well tolerated in this patient population.
In two multicenter, double-blind, placebo controlled studies, a total of 235 normotensive patients with insulin-dependent diabetes mellitus, retinopathy and microalbuminuria (20-200 mcg/min) were randomized to placebo or captopril (50 mg b.i.d.) and followed for up to 2 years. Captopril delayed the progression to overt nephropathy (proteinuria ≥ 500 mg/day) in both studies (risk reduction 67% to 76%; P<0.05). Captopril also reduced the albumin excretion rate. However, the long term clinical benefit of reducing the progression from microalbuminuria to proteinuria has not been established.
Studies in rats and cats indicate that captopril does not cross the blood-brain barrier to any significant extent.
Captopril tablets are indicated for the treatment of hypertension.
In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS).
Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations.
Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive.
Heart Failure
Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment.
Left Ventricular Dysfunction After Myocardial Infarction
Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients.
Diabetic Nephropathy
Captopril is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).
In considering use of captopril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema).
Anaphylactoid and Possibly Related Reactions
Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including captopril) may be subject to a variety of adverse reactions, some of them serious.
Head and Neck Angioedema
Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been seen in patients treated with ACE inhibitors, including captopril. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Emergency therapy, including but not necessarily limited to, subcutaneous administration of a 1:1000 solution of epinephrine should be promptly instituted.
Swelling confined to the face, mucous membranes of the mouth, lips and extremities has usually resolved with discontinuation of captopril; some cases required medical therapy. (See PRECAUTIONS: Information for Patients and ADVERSE REACTIONS.)
Intestinal Angioedema
Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.
Anaphylactoid reactions during desensitization
Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.
Anaphylactoid reactions during membrane exposure
Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.
Neutropenia (<1000/mm3) with myeloid hypoplasia has resulted from use of captopril. About half of the neutropenic patients developed systemic or oral cavity infections or other features of the syndrome of agranulocytosis.
The risk of neutropenia is dependent on the clinical status of the patient:
In clinical trials in patients with hypertension who have normal renal function (serum creatinine less than 1.6 mg/dL and no collagen vascular diseases), neutropenia has been seen in one patient out of over 8600 exposed.
In patients with some degree of renal failure (serum creatinine at least 1.6 mg/dL) but no collagen vascular disease, the risk of neutropenia in clinical trials was about 1 per 500, a frequency over 15 times that for uncomplicated hypertension. Daily doses of captopril were relatively high in these patients, particularly in view of their diminished renal function. In foreign marketing experience in patients with renal failure, use of allopurinol concomitantly with captopril has been associated with neutropenia but this association has not appeared in U.S. reports.
In patients with collagen vascular diseases (e.g., systemic lupus erythematosus, scleroderma) and impaired renal function, neutropenia occurred in 3.7 percent of patients in clinical trials.
While none of the over 750 patients in formal clinical trials of heart failure developed neutropenia, it has occurred during the subsequent clinical experience. About half of the reported cases had serum creatinine ≥1.6 mg/dL and more than 75 percent were in patients also receiving procainamide. In heart failure, it appears that the same risk factors for neutropenia are present.
The neutropenia has usually been detected within three months after captopril was started. Bone marrow examinations in patients with neutropenia consistently showed myeloid hypoplasia, frequently accompanied by erythroid hypoplasia and decreased numbers of megakaryocytes (e.g., hypoplastic bone marrow and pancytopenia); anemia and thrombocytopenia were sometimes seen.
In general, neutrophils returned to normal in about two weeks after captopril was discontinued, and serious infections were limited to clinically complex patients. About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors.
Evaluation of the hypertensive or heart failure patients should always include assessment of renal function.
If captopril is used in patients with impaired renal function, white blood cell and differential counts should be evaluated prior to starting treatment and at approximately two-week intervals for about three months, then periodically.
In patients with collagen vascular disease or who are exposed to other drugs known to affect the white cells or immune response, particularly when there is impaired renal function, captopril should be used only after an assessment of benefit and risk, and then with caution.
All patients treated with captopril should be told to report any signs of infection (e.g., sore throat, fever). If infection is suspected, white cell counts should be performed without delay.
Since discontinuation of captopril and other drugs has generally led to prompt return of the white count to normal, upon confirmation of neutropenia (neutrophil count <1000/mm3) the physician should withdraw captopril and closely follow the patient's course.
Total urinary proteins greater than 1 g per day were seen in about 0.7 percent of patients receiving captopril. About 90 percent of affected patients had evidence of prior renal disease or received relatively high doses of captopril (in excess of 150 mg/day), or both. The nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within six months whether or not captopril was continued. Parameters of renal function, such as BUN and creatinine, were seldom altered in the patients with proteinuria.
Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis. (See PRECAUTIONS: Drug Interactions.)
In heart failure, where the blood pressure was either normal or low, transient decreases in mean blood pressure greater than 20 percent were recorded in about half of the patients. This transient hypotension is more likely to occur after any of the first several doses and is usually well tolerated, producing either no symptoms or brief mild lightheadedness, although in rare instances it has been associated with arrhythmia or conduction defects. Hypotension was the reason for discontinuation of drug in 3.6 percent of patients with heart failure.
BECAUSE OF THE POTENTIAL FALL IN BLOOD PRESSURE IN THESE PATIENTS, THERAPY SHOULD BE STARTED UNDER VERY CLOSE MEDICAL SUPERVISION. A starting dose of 6.25 or 12.5 mg tid may minimize the hypotensive effect. Patients should be followed closely for the first two weeks of treatment and whenever the dose of captopril and/or diuretic is increased. In patients with heart failure, reducing the dose of diuretic, if feasible, may minimize the fall in blood pressure.
Hypotension is not per se a reason to discontinue captopril. Some decrease of systemic blood pressure is a common and desirable observation upon initiation of captopril treatment in heart failure. The magnitude of the decrease is greatest early in the course of treatment; this effect stabilizes within a week or two, and generally returns to pretreatment levels, without a decrease in therapeutic efficacy, within two months.
Fetal/Neonatal Morbidity and Mortality
ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.
The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure.
These adverse effects do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of captopril as soon as possible.
Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses and serial ultrasound examinations should be performed to assess the intraamniotic environment.
If oligohydramnios is observed, captopril should be discontinued unless it is considered life-saving for the mother. Contraction stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.
Infants with histories of in utero exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. While captopril may be removed from the adult circulation by hemodialysis, there is inadequate data concerning the effectiveness of hemodialysis for removing it from the circulation of neonates or children. Peritoneal dialysis is not effective for removing captopril; there is no information concerning exchange transfusion for removing captopril from the general circulation.
When captopril was given to rabbits at doses about 0.8 to 70 times (on a mg/kg basis) the maximum recommended human dose, low incidences of craniofacial malformations were seen. No teratogenic effects of captopril were seen in studies of pregnant rats and hamsters. On a mg/kg basis, the doses used were up to 150 times (in hamsters) and 625 times (in rats) the maximum recommended human dose.
Hepatic Failure
Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.
Some patients with renal disease, particularly those with severe renal artery stenosis, have developed increases in BUN and serum creatinine after reduction of blood pressure with captopril. Captopril dosage reduction and/or discontinuation of diuretic may be required. For some of these patients, it may not be possible to normalize blood pressure and maintain adequate renal perfusion.
Heart Failure
About 20 percent of patients develop stable elevations of BUN and serum creatinine greater than 20 percent above normal or baseline upon long-term treatment with captopril. Less than 5 percent of patients, generally those with severe preexisting renal disease, required discontinuation of treatment due to progressively increasing creatinine; subsequent improvement probably depends upon the severity of the underlying renal disease.
See CLINICAL PHARMACOLOGY, DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS: Altered Laboratory Findings.
Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including captopril. When treated with ACE inhibitors, patients at risk for the development of hyperkalemia include those with: renal insufficiency; diabetes mellitus; and those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes; or other drugs associated with increases in serum potassium. In a trial of type I diabetic patients with proteinuria, the incidence of withdrawal of treatment with captopril for hyperkalemia was 2% (4/207). In two trials of normotensive type I diabetic patients with microalbuminuria, no captopril group subjects had hyperkalemia (0/116). (See PRECAUTIONS: Information for Patients and Drug Interactions; ADVERSE REACTIONS: Altered Laboratory Findings.)
Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough.
Valvular Stenosis
There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others.
In patients undergoing major surgery or during anesthesia with agents that produce hypotension, captopril will block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.
Recent clinical observations have shown an association of hypersensitivity-like (anaphylactoid) reactions during hemodialysis with high-flux dialysis membranes (e.g., AN69) in patients receiving ACE inhibitors. In these patients, consideration should be given to using a different type of dialysis membrane of a different class medication. (See WARNINGS: Anaphylactoid reactions during membrane exposure.)
Information for Patients
Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema (e.g., swelling of face, eyes, lips, tongue, larynx and extremities; difficulty in swallowing or breathing; hoarseness) and to discontinue therapy. (See WARNINGS: Head and Heck Angioedema and Intestinal Angioedema.)
Patients should be told to report promptly any indication of infection (e.g., sore throat, fever), which may be a sign of neutropenia, or of progressive edema which might be related to proteinuria and nephrotic syndrome.
All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. The causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.
Patients should be advised not to use potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes without consulting their physician. (See PRECAUTIONS: General and Drug Interactions; ADVERSE REACTIONS.)
Patients should be warned against interruption or discontinuation of medication unless instructed by the physician.
Heart failure patients on captopril therapy should be cautioned against rapid increases in physical activity.
Patients should be informed that captopril should be taken one hour before meals (see DOSAGE AND ADMINISTRATION).
Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE-inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.
Hypotension-Patients on Diuretic Therapy
Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril or initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least one hour after the initial dose. If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline. This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion.
Agents Having Vasodilator Activity
Data on the effect of concomitant use of vasodilators in patients receiving captopril for heart failure are not available; therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril. If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower dosage.
Agents Causing Renin Release
Captopril's effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.
Agents Affecting Sympathetic Activity
The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution. Beta-adrenergic blocking drugs add some further anti-hypertensive effect to captopril, but the overall response is less than additive.
Agents Increasing Serum Potassium
Since captopril decreases aldosterone production, elevation of serum potassium may occur. Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Salt substitutes containing potassium should also be used with caution.
Inhibitors of Endogenous Prostaglandin Synthesis
It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension. Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.
Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coadministered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of lithium toxicity.
Cardiac Glycosides
In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.
Loop Diuretics
Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.
Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including captopril.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Two-year studies with doses of 50 to 1350 mg/kg/day in mice and rats failed to show any evidence of carcinogenic potential. The high dose in these studies is 150 times the maximum recommended human dose of 450 mg, assuming a 50-kg subject. On a body-surface-area basis, the high doses for mice and rats are 13 and 26 times the maximum recommended human dose, respectively.
Studies in rats have revealed no impairment of fertility.
Animal Toxicology
Chronic oral toxicity studies were conducted in rats (2 years), dogs (47 weeks; 1 year), mice (2 years), and monkeys (1 year). Significant drug related toxicity included effects on hematopoiesis, renal toxicity, erosion/ulceration of the stomach, and variation of retinal blood vessels.
Reductions in hemoglobin and/or hematocrit values were seen in mice, rats, and monkeys at doses 50 to 150 times the maximum recommended human dose (MRHD) of 450 mg, assuming a 50-kg subject. On a body-surface-area-basis, these doses are 5 to 25 times maximum recommended dose (MRHD). Anemia, leukopenia, thrombocytopenia, and bone marrow suppression occurred in dogs at doses 8 to 30 times MRHD on a body-weight basis (4 to 15 times MRHD on a surface-area basis). The reductions in hemoglobin and hematocrit values in rats and mice were only significant at 1 year and returned to normal with continued dosing by the end of the study. Marked anemia was seen at all dose levels (8 to 30 times MRHD) in dogs, whereas moderate to marked leukopenia was noted only at 15 and 30 times MRHD and thrombocytopenia at 30 times MRHD. The anemia could be reversed upon discontinuation of dosing. Bone marrow suppression occurred to a varying degree, being associated only with dogs that died or were sacrificed in a moribund condition in the 1 year study. However, in the 47-week study at a dose 30 times MRHD, bone marrow suppression was found to be reversible upon continued drug administration.
Captopril caused hyperplasia of the juxtaglomerular apparatus of the kidneys in mice and rats at doses 7 to 200 times MRHD on a body-weight basis (0.6 to 35 times MRHD on a surface-area basis); in monkeys at 20 to 60 times MRHD on a body-weight basis (7 to 20 times MRHD on a surface-area basis); and in dogs at 30 times MRHD on a body-weight basis (15 times MRHD on a surface-area basis).
Gastric erosion/ulcerations were increased in incidence in male rats at 20 to 200 times MRHD on a body-weight basis (3.5 and 35 times MRHD on a surface-area basis); in dogs at 30 times MRHD on a body-weight basis (15 times on MRHD on a surface-area basis); and in monkeys at 65 times MRHD on a body-weight basis (20 times MRHD on a surface-area basis). Rabbits developed gastric and intestinal ulcers when given oral doses approximately 30 times MRHD on a body-weight basis (10 times MRHD on surface-area basis) for only 5 to 7 days.
In the two-year rat study, irreversible and progressive variations in the caliber of retinal vessels (focal sacculations and constrictions) occurred at all dose levels (7 to 200 times MRHD) on a body-weight basis; 1 to 35 times MRHD on a surface-area basis in a dose-related fashion. The effect was first observed in the 88th week of dosing, with a progressively increased incidence thereafter, even after cessation of dosing.
Teratogenic Effects: Categories C (first trimester) and D (second and third trimesters)
Nursing Mothers
Concentrations of captopril in human milk are approximately one percent of those in maternal blood. Because of the potential for serious adverse reactions in nursing infants from captopril, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of captopril to the mother. (See PRECAUTIONS: Pediatric Use.)
Pediatric Use
Safety and effectiveness in pediatric patients have not been established. There is limited experience reported in the literature with the use of captopril in the pediatric population; dosage, on a weight basis, was generally reported to be comparable to or less than that used in adults.
Infants, especially newborns, may be more susceptible to the adverse hemodynamic effects of captopril. Excessive, prolonged and unpredictable decreases in blood pressure and associated complications, including oliguria and seizures, have been reported.
Captopril should be used in pediatric patients only if other measures for controlling blood pressure have not been effective.
Reported incidences are based on clinical trials involving approximately 7000 patients.
Renal: About one of 100 patients developed proteinuria (see WARNINGS).
Each of the following has been reported in approximately 1 to 2 of 1000 patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, nephrotic syndrome, polyuria, oliguria, and urinary frequency.
Hematologic: Neutropenia/agranulocytosis has occurred (see WARNINGS). Cases of anemia, thrombocytopenia, and pancytopenia have been reported.
Dermatologic: Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about 4 to 7 (depending on renal status and dose) of 100 patients, usually during the first four weeks of therapy. It is usually maculopapular, and rarely urticarial. The rash is usually mild and disappears within a few days of dosage reduction, short-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. Pruritus, without rash, occurs in about 2 of 100 patients. Between 7 and 10 patients with skin rash have shown an eosinophilia and/or positive ANA titers. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported.
Flushing or pallor has been reported in 2 to 5 of 1000 patients.
Cardiovascular: Hypotension may occur; see WARNINGS and PRECAUTIONS: Drug Interactions for discussion of hypotension with captopril therapy.
Tachycardia, chest pain, and palpitations have each been observed in approximately 1 of 100 patients.
Angina pectoris, myocardial infarction, Raynaud's syndrome and congestive heart failure have each occurred in 2 to 3 of 1000 patients.
Dysgeusia: Approximately 2 to 4 (depending on renal status and dose) of 100 patients developed a diminution or loss of taste perception. Taste impairment is reversible and usually self-limited (2 to 3 months) even with continued drug administration. Weight loss may be associated with the loss of taste.
Angioedema: Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in 1000 patients. Angioedema involving the upper airways has caused fatal airway obstruction. (See WARNINGS: Head and Neck Angioedema, Intestinal Angioedema and PRECAUTIONS: Information for Patients.)
Cough: Cough has been reported in 0.5 to 2% of patients treated with captopril in clinical trials (see PRECAUTIONS: General: Cough).
The following have been reported in about 0.5 to 2 percent of patients but did not appear at increased frequency compared to placebo or other treatments used in controlled trials; gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, aphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, alopecia, paresthesias.
Other clinical adverse effects reported since the drug was marketed are listed below by body system. In this setting, an incidence or causal relationship cannot be accurately determined.
Body as a Whole: Anaphylactoid reactions (see WARNINGS: Anaphylactoid and Possible Related Reactions and PRECAUTIONS: Hemodialysis).
General: Asthenia, gynecomastia.
Cardiovascular: Cardiac arrest, cerebrovascular accident/insufficiency, rhythm disturbances, orthostatic hypotension, syncope.
Dermatologic: Bullous pemphigus, erythema multiforme (including Stevens-Johnson syndrome), exfoliative dermatitis.
Gastrointestinal: Pancreatitis, glossitis, dyspepsia.
Hematologic: Anemia, including aplastic and hemolytic.
Hepatobiliary: Jaundice, hepatitis, including rare cases of necrosis, cholestasis.
Metabolic: Symptomatic hyponatremia.
Musculoskeletal: Myalgia, myasthenia.
Nervous/Psychiatric: Ataxia, confusion, depression, nervousness, somnolence.
Respiratory: Bronchospasm, eosinophilic pneumonitis, rhinitis.
Special Senses: Blurred vision.
Urogenital: Impotence.
As with other ACE inhibitors, a syndrome has been reported which may include: fever, myalgia, arthralgia, interstitial nephritis, vasculitis, rash or other dermatologic manifestations, eosinophilia and an elevated ESR.
Fetal/Neonatal Morbidity and Mortality
Altered Laboratory Findings
Serum Electrolytes: Hyperkalemia: Small increases in serum potassium, especially in patients with renal impairment (see PRECAUTIONS).
Hyponatremia: Particularly in patients receiving a low sodium diet or concomitant diuretics.
BUN/Serum Creatinine: Transient elevations of BUN or serum creatinine especially in volume or salt depleted patients or those with renovascular hypertension may occur. Rapid reduction of long-standing or markedly elevated blood pressure can result in decreases in the glomerular filtration rate and, in turn, lead to increases in BUN or serum creatinine.
Hematologic: A positive ANA has been reported.
Liver Funtion Tests: Elevations of liver transaminases, alkaline phosphatase, and serum bilirubin have occurred.
Correction of hypotension would be of primary concern. Volume expansion with an intravenous infusion of normal saline is the treatment of choice for restoration of blood pressure.
While captopril may be removed from the adult circulation by hemodialysis, there is inadequate data concerning the effectiveness of hemodialysis for removing it from the circulation of neonates or children. Peritoneal dialysis is not effective for removing captopril; there is no information concerning exchange transfusion for removing captopril from the general circulation.
Captopril should be taken one hour before meals. Dosage must be individualized.
Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of blood pressure elevation, salt restriction, and other clinical circumstances. If possible, discontinue the patient's previous antihypertensive drug regimen for one week before starting captopril.
The initial dose of captopril is 25 mg b.i.d. or t.i.d. If satisfactory reduction of blood pressure has not been achieved after one or two weeks, the dose may be increased to 50 mg b.i.d. or t.i.d. Concomitant sodium restriction may be beneficial when captopril is used alone.
The dose of captopril in hypertension usually does not exceed 50 mg t.i.d. Therefore, if the blood pressure has not been satisfactorily controlled after one to two weeks at this dose, (and the patient is not already receiving a diuretic), a modest dose of thiazide-type diuretic (e.g., hydrochlorothiazide, 25 mg daily), should be added. The diuretic dose may be increased at one- to two-week intervals until its highest usual antihypertensive dose is reached.
If captopril is being started in a patient already receiving a diuretic, captopril therapy should be initiated under close medical supervision (see WARNINGS and PRECAUTIONS: Drug Interactions regarding hypotension), with dosage and titration of captopril as noted above.
If further blood pressure reduction is required, the dose of captopril may be increased to 100 mg b.i.d. or t.i.d. and then, if necessary, to 150 mg b.i.d. or t.i.d. (while continuing the diuretic). The usual dose range is 25 to 150 mg b.i.d. or t.i.d. A maximum daily dose of 450 mg captopril should not be exceeded.
For patients with severe hypertension (e.g., accelerated or malignant hypertension), when temporary discontinuation of current antihypertensive therapy is not practical or desirable, or when prompt titration to more normotensive blood pressure levels is indicated, diuretic should be continued but other current antihypertensive medication stopped and captopril dosage promptly initiated at 25 mg b.i.d. or t.i.d., under close medical supervision.
When necessitated by the patient's clinical condition, the daily dose of captopril may be increased every 24 hours or less under continuous medical supervision until a satisfactory blood pressure response is obtained or the maximum dose of captopril is reached. In this regimen, addition of a more potent diuretic, e.g., furosemide, may also be indicated.
Beta-blockers may also be used in conjunction with captopril therapy (see PRECAUTIONS: Drug Interactions), but the effects of the two drugs are less than additive.
Heart Failure
Initiation of therapy requires consideration of recent diuretic therapy and the possibility of severe salt/volume depletion. In patients with either normal or low blood pressure, who have been vigorously treated with diuretics and who may be hyponatremic and/or hypovolemic, a starting dose of 6.25 or 12.5 mg tid may minimize the magnitude or duration of the hypotensive effect (see WARNINGS: Hypotension); for these patients, titration of the usual daily dosage can then occur within the next several days.
For most patients the usual initial daily dosage is 25 mg tid. After a dose of 50 mg tid is reached, further increases in dosage should be delayed, where possible, for at least two weeks to determine if a satisfactory response occurs. Most patients studied have had a satisfactory clinical improvement at 50 or 100 mg tid. A maximum daily dose of 450 mg of captopril should not be exceeded.
Captopril should generally be used in conjunction with a diuretic and digitalis. Captopril therapy must be initiated under very close medical supervision.
Left Ventricular Dysfunction After Myocardial Infarction
The recommended dose for long-term use in patients following a myocardial infarction is a target maintenance dose of 50 mg t.i.d.
Therapy may be initiated as early as three days following a myocardial infarction. After a single dose of 6.25 mg, captopril therapy should be initiated at 12.5 mg t.i.d. Captopril should then be increased to 25 mg t.i.d. during the next several days and to a target dose of 50 mg t.i.d. over the next several weeks as tolerated (see CLINICAL PHARMACOLOGY).
Captopril may be used in patients treated with other post-myocardial infarction therapies, e.g., thrombolytics, aspirin, beta blockers.
Diabetic Nephropathy
The recommended dose of captopril for long term use to treat diabetic nephropathy is 25 mg t.i.d.
Other antihypertensives such as diuretics, beta blockers, centrally acting agents or vasodilators may be used in conjunction with captopril if additional therapy is required to further lower blood pressure.
Dosage Adjustment in Renal Impairment
Because captopril is excreted primarily by the kidneys, excretion rates are reduced in patients with impaired renal function. These patients will take longer to reach steady-state captopril levels and will reach higher steady-state levels for a given daily dose than patients with normal renal function. Therefore, these patients may respond to smaller or less frequent doses.
Accordingly, for patients with significant renal impairment, initial daily dosage of captopril should be reduced, and smaller increments utilized for titration, which should be quite slow (one- to two-week intervals). After the desired therapeutic effect has been achieved, the dose should be slowly back-titrated to determine the minimal effective dose. When concomitant diuretic therapy is required, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic, is preferred in patients with severe renal impairment. (See also WARNINGS: Anaphylactoid reactions during membrane exposure and PRECAUTIONS: Hemodialysis.)
Captopril Tablets, USP are available as follows:
12.5 mg - White, Round, Scored Tablets; Debossed "W7".
25 mg - White, Round, Quadrisect Scored Tablets; Debossed "WW 172".
50 mg - White, Oblong, Bisect Scored Tablets; Debossed "WW 173".
100 mg - White, Oblong Tablets, Bisect Scored; Debossed "WW 174".
Captopril tablets may exhibit a slight sulfurous odor.
They are supplied by State of Florida DOH Central Pharmacy as follows:
NDC Strength Quantity/Form Color Source Prod. Code 53808-0217-1 50 mg 30 Tablets in a Blister Pack WHITE 0143-1173 53808-0359-1 100 mg 30 Tablets in a Blister Pack WHITE 0143-1174
Store at 20-25°C (68-77°F). [See USP Controlled Room Temperature].
Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
Manufactured by:
West-ward Pharmaceutical Corp.
Eatontown, NJ 07724
And Repackaged By:
State of Florida DOH Central Pharmacy
104-2 Hamilton Park Drive
Tallahassee, FL 32304
United States
captopril tablet
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:53808-0217(NDC:0143-1173) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CAPTOPRIL (UNII: 9G64RSX1XD) (CAPTOPRIL - UNII:9G64RSX1XD) CAPTOPRIL 50 mg Inactive Ingredients Ingredient Name Strength ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) STARCH, CORN (UNII: O8232NY3SJ) STEARIC ACID (UNII: 4ELV7Z65AP) Product Characteristics Color WHITE Score 2 pieces Shape OVAL Size 8mm Flavor Imprint Code WW;173 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:53808-0217-1 30 in 1 BLISTER PACK; Type 0: Not a Combination Product 07/01/2009 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA074505 07/01/2009 CAPTOPRIL
captopril tablet
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:53808-0359(NDC:0143-1174) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CAPTOPRIL (UNII: 9G64RSX1XD) (CAPTOPRIL - UNII:9G64RSX1XD) CAPTOPRIL 100 mg Inactive Ingredients Ingredient Name Strength ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) STARCH, POTATO (UNII: 8I089SAH3T) STEARIC ACID (UNII: 4ELV7Z65AP) Product Characteristics Color WHITE Score 2 pieces Shape OVAL Size 9mm Flavor Imprint Code WW;174 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:53808-0359-1 30 in 1 BLISTER PACK; Type 0: Not a Combination Product 07/01/2009 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA074505 07/01/2009 Labeler - DOH CENTRAL PHARMACY (829348114) Establishment Name Address ID/FEI Business Operations DOH CENTRAL PHARMACY 829348114 repack(53808-0217, 53808-0359)


text:
It is a circular mouse pad made of soft synthetic leather.
Washing method
Precautions for Purchase
|Size (inch)
All of Marpple's products are personalized products required by customers. Therefore, we do not accept
returns for refund or exchange, at the exception of items damaged in transit.
To be eligible for a refund or exchange, you must first email us within 7 days of receiving the products at email@example.com with pictures of the damaged items.
Please note that design edits are only available at the stage of 'Order Placed'. During the 'Processing' stage, any design changes or cancellation is not available. If you need design changes after your order please contact us through our chat system or via email.

subset: commoncrawl


text:
The Islamic Republic of Iran has been occupied since 4000BCE, making Iran home to the world's oldest continuous civilization.
It is located in central Eurasia on two ancient trade routes. One runs North-South and connects the Caspian Sea to the Persian Gulf, the other one goes East-West between China, India, Europe and Africa.
There's a city called Isfahan at the intersection of these two routes, which at one time was the wealthiest city in the world. Isfahan was twice the capital of the Persian Empire, during the Median and then Safavid Dynasties.
Interesting artifacts from pre-Islamic Persia include the cylinder of Cyrus the Great, which is the world's first written declaration of human rights. The hanging gardens of Babylon (one of the seven wonders of the ancient world) and the Code of Hammurabi (a set of rules which outlast the King) are also on the list.
The Persian Empire was so magnificent that returning Crusaders carried tales of its splendor and helped spark the Renaissance in Europe! Influence of the Zoroastrian teachings of equality also inspired Greek philosophers such as Aristotle and Socrates.
The Persian Empire was conquered by Muslim Arabs around 650CE during the Sassanid Dynasty. Initially the Zoroastrian, Christian and Jewish faiths were tolerated but by 1000CE most Persians had accepted Islam.
In the sixteenth century Shi'a Islam was declared in Isfahan to be the national religion of Persia and the second golden age began. From 1500 to 1720 the Safavid Dynasty built the greatest Iranian empire since before the Islamic conquest of Persia.
Because of its strategic location and oil resources, World War I found Persia in the middle of conflicts between the Ottoman Empire, Russia and the British Empire-via-India. Persia became Iran as of 1935 and was ruled by the Shah, a Persian term for "monarch."
In the Islamic Revolution of 1979 Iran re-established a theocratic government under the Ayatollah Khomeini.
Today the capital of Iran is the city of Tehran, and Iran is known as the world's center of Shi'a Islam.
Text by Steve Smith.


text: Book a Private Event Partyplanner East Meadow Home Party Request When Is Your Event? Let's make sure our schedule matches yours. Tell us your preferred date and time, and within 1 business day we'll either confirm your date or offer an alternative. You can also call us at (516) 390-8740. Desired Date Desired Time Of Day Choose Time Morning (to 12pm) Afternoon (12pm to 5pm) Evening (5pm - 9pm) Late Evening (9pm on) Your Information First Name Last Name Company Phone Number Email Address Request Event Date How It Works Request an event date. We'll call or email you to confirm your date. Book your event with a deposit. Questions? Give us a call at (516) 390-8740 Back to Top


text:
>>Badarpur >>Ballabgarh >>Chhainsa >>Daulatabad >>Faridabad >>Palwal
You can find faridabad Allahabad Bank NEFT, RTGS and IMPS codes in the table alongside. Allahabad Bank NEFT or RTGS or IMPS code is nothing but IFSC code and used in net banking. Now-a-days everybody needs quick banking solutions as it saves a lot of time. For carrying out these transactions all we need is account details and IFSC code. There are basically three types of transfers NEFT, RTGS and IMPS. The difference between them is that NEFT transfers are carried out in batches and RTGS transactions are carried out individually. IMPS is a mobile platform where funds can be transferred 24x7. These fund transfer systems can be used for various purposes like bill payments, insurance premium payments, Loan EMI payments, online purchases, paperless fund transfers, etc.
Allahabad Bank IFSC code in faridabad in Haryana state is used in internet banking for transferring funds between any two bank branches. These IFSC codes for Allahabad Bank faridabad are used to identify the branches participating in online transactions via RTGS, NEFT and IMPS systems. Therefore, each branch of Allahabad Bank in faridabad supporting net banking has its unique IFSC code. Allahabad Bank IFSC code list in faridabad is provided by RBI. NOTE that all branches of a bank cannot provide online fund transfer systems, only those approved by RBI can provide such facility.
Allahabad Bank faridabad IFSC codes are given in the table alongside. Details like address and contact numbers of branches of Allahabad Bank with IFSC code in faridabad are also provided. Simplify your search either by selecting any particular city from the drop down list or by selecting the link for city in the table on the right side. You can find IFSC codes for all Allahabad Bank faridabad branches here.
You can search through IFSC Codes of Allahabad Bank in faridabad District of Haryana State by using the search box or you can browse through the table using the conrols at the bottom.


text:
- Home
- Make Cheap Calls
- How to Dial
- Dialing Codes
- Call from...
- Calling Info
- Related Services
- Local Info
- Help
Quick Links
World Local Times
* daylight savings time
Call Ottawa from...
Ottawa Facts
Ottawa Virtual Phone Numbers
A virtual telephone number is a phone number used specifically as a forwarding number. Incoming calls to the virtual number are automatically forwarded to another telephone number that you designate - the destination number.
Virtual numbers are also known as DID or direct inward dialing numbers.
Virtual numbers are often coupled with a VoIP phone service as a means to make cheap international phone calls. But virtual numbers can also be used over traditional phone networks, too, though the cost will generally be higher.
The incoming calls can be forwarded any distance - locally, nationally, or internationally - and to any type of receiving number - landline, mobile, fax machine.
There are two basic types of virtual phone numbers: virtual local numbers and virtual toll-free numbers. Each forwards incoming calls in a similar manner, but number availability and cost may differ significantly. Either type can be forwarded to a VoIP service.
When buying a virtual number, you normally are buying buy two things: the actual phone number and the forwarding service that routes calls to the destination number. How these two items are 'packaged' varies from vendor to vendor.
For the caller, the cost of the call is just the leg associated with reaching the virtual local or toll-free number. In most cases, this is going to be free to the caller.
For the virtual number subscriber, the cost includes at least the subscription fee for maintaining the number and the costs for the 'forwarded' leg of the incoming calls. In the case of a toll-free virtual number, it will also include the inbound leg of the call to the toll-free number.
Read on for additional information and recommended vendors for Ottawa virtual numbers. Topics covered:
Virtual Phone Numbers in Ottawa
Virtual telephone numbers are readily available for Ottawa, Ontario area codes. They are also available for nearby area codes.
Virtual numbers located in other area codes or countries can be forwarded to Ottawa area codes without no problems.
Virtual Numbers in Ottawa for Outbound Calling
Virtual phone numbers with Ottawa area codes are readily available and can be bought from a variety of providers.
See the list of recommended providers below for suggestions.
Inbound calls received at a Ottawa virtual number can be forwarded anywhere in the world. Forwarding costs will vary depending on the location and the provider you use.
Forwarding a Virtual Number to Ottawa
Virtual numbers located in other area codes or other countries can be easily forwarded to a destination number in Ottawa. There are no restrictions on forwarding calls to Ottawa numbers.
Recommended Virtual Number Providers
The table below identifies several vendors you can buy Ottawa virtual phone numbers from. We've personally checked out all these vendors to confirm that their pricing and rates are reasonable.
In all cases, you will need to buy both the virtual number itself and the call forwarding service to route incoming calls to your destination. You cannot easily separate these two elements.
Each company offers something slightly different, so we suggest you look at a few of them to see what works best for you. In addition to price, other factors that may influence your choice could include:
In most cases, we have tried to find vendors focused on serving individual consumers as opposed to business customers. Business customers tend to have additional needs - like sophisticated call tracking and logging analytics - that are not required by consumers.
Figures in US$, unless otherwise stated
Check provider websites for current prices
* Applicable per minute rates charged for the forwarded leg of the call
** iNum is a 'global' virtual number with a unique country code (+883). Inbound dialing to +883 numbers is widely, but not universally supported. More on iNum
What is a 'Virtual Phone Number'?
A virtual telephone number is a phone number used to forward incoming phone calls on to another telephone number - the 'destination number'.
Virtual numbers can be used for many reasons by both consumers and businesses. Some examples:
Virtual phone numbers come in two flavors:
Both types of virtual numbers work roughly the same way, except for 2 main differences.
One difference is that virtual local numbers are free to the inbound caller if the the number's area code is included as part of the caller's calling plan. Callers from outside the local service area would need to pay any long-distance charges themselves. For example, if you had a local virtual number for Ottawa, then callers from in and around the Ottawa service area would be able to call that number for free. As well, people on nationwide calling plans might also be able to call the number for free.
In contrast, with a toll-free number the inbound caller pays normally nothing regardless of where they are calling from - any long distance charges are passed along to the toll-free number subscriber.
The second main difference is the monthly cost of a local vs. toll-free virtual numbers to the virtual number owner / subscriber. Generally, toll-free virtual numbers are considerably more expensive than local virtual phone numbers. Not only does the toll-free number have a higher baseline monthly subscription cost, but also the toll-free subscriber must pay any charges related to inbound leg of any calls.
As a result, toll-free virtual numbers are generally not a viable cost saving solution for individuals, though they may work well for businesses.
How Virtual Phone Numbers Work
Virtual numbers are used to forward incoming calls to another location - usually in another part of the country or in another country altogether.
Generally, the incoming calls to the virtual number are forwarded to their destination via VoIP internet calling technology. Given that VoIP telephony is much less expensive than traditional telephony, this allows either the inbound caller or the virtual number subscriber or both to reduce calling costs.
To be clear, virtual numbers can be forwarded over traditional telephone networks, too - but it will cost more.
Unlike normal phone numbers, virtual telephone numbers generally do not have an actual physical landline or mobile phone assigned to them. Meaning that they don't actually ring anywhere.
Instead, virtual phone numbers are used as a mechanism to get the incoming call onto the telephone network - sort of like an entry ramp onto a roadway. Once 'received', the calls are then immediately routed forward to the end destination telephone.
Virtual telephone numbers can be forwarded to any type of end destination phone number - a mobile phone, a landline phone, a VoIP phone number, a fax machine, etc. The end destination number can be domestic or overseas.
Typically, the destination number can be easily designated using an account management interface. The subscriber simply specifies what end destination number they want to use - whether for a few hours or forever.
Assuming they are available, virtual phone numbers work much like a regular landline or toll-free phone number in terms of billing and payment. You subscribe to the service and then pay a monthly fee. The exact cost is determined by the provider, the calling plan you select, and the rates to the destination number, among other factors.
Availability of Virtual Phone Numbers
Virtual telephone numbers are available for purchase in many countries around the world - but not available in many others. For instance, virtual numbers are not allowed in India as of this writing.
In general, countries that restrict use of virtual numbers are also countries that regulate use of VoIP internet telephony - and, usually, telecom markets in general.
In such countries, governments are typically trying to nuture incumbent telephone companies and protect them from low-cost competitors, especially from low-cost VoIP companies.
In countries with liberal telecom regulation, like Canada, virtual numbers are easy to obtain with few, if any, restrictions on their use.
Related Pages
Sorry, no related content.
★ 2010 Editor's Choice ★
As rated by AboutCallingCards.com, the leading consumer guide to calling cards.
☆ Learn More ☆
Recommended Calling Cards
We recommend these calling cards for making
Recommended VoIP Services
We recommend these VoIP providers for making
Related Services


text:
Explore More Collections See More
See All Best Sellers
See All Collection
See All Best Sellers
See All Collection
Canvas Prints Wall Art - Watercolor Style Abstract Autumn Tree | Modern Wall Decor/Home Art Gallery Wraps Giclee Print & Wood Framed. Ready to Hang - 12" x 12"
- Make sure this fits by entering your model number.
- High quality printed canvas stretched and stapled to durable shrink resistant frames.
- 1.50" thick stretcher bars for gallery quality profile.
- Canvases are printed and hand stretched in the USA by professionals.
- Hanging accessory kit included.
- All Wall26 Products are made in and shipped from the USA.Be aware of counterfeit sellers with inferior products. Our products will never ship from China or overseas.
We use high quality canvases which are designed specifically for canvas printing. Our canvas is a white semi-gloss artists canvas. We use latest HP Latex inks during printing process allowing our products to be fade resistant for up to 100 years. Canvas pictures are stretched on wooden stretcher frames. All frames are of the highest quality.
Browse More Wall Art


text:
The Ricordi Online Numerical Catalogue expresses and embodies the celebrated Milanese musical publishing house's activity. All the works acquired by the company, founded by Giovanni Ricordi in 1808, are present in numerical order roughly corresponding to chronological order. They are described with their essential information for the identification of the compositions, including the sale prices at the dates of the publication of the catalogue's two volumes, information that makes it possible to identify many first editions. The two volumes of the catalogue, an important bibliographic resource for the history of music and music publishing from 1808 to 1870 in Italy and Europe, are here made available online. They contain 43,025 entries. This online version may be consulted easily by catalogue number, by author, by the title of the composition, and by the date of publication (or acquisition) by the editor Ricordi.
|Cat. Number
Vorisek, Jan Hugo
Impromptus pour Piano. Op. 7
Vorisek, Jan Hugo
Variat. bril. pour Piano sur le thême fav., La Sentinelle. Op. 6


text: Skogman Insurance is committed to providing you with the best customer service to meet your insurance needs. Have a question about your policy? Checking on a claim? Have you been in an accident? We're here to help. Call us at 319-366-6288. Or fill out the form below and we'll contact you shortly.


text:
Avg Walkscore in Ferriday: 24
/ Parish Avg 18
Should you require assistance in navigating our website or searching for real estate,
please contact our offices at
The multiple listing information is provided by the Greater Baton Rouge Association of REALTORS®, Inc. multiple listing service from a copyrighted compilation of listings. The compilation of listings and each individual listing are ©2023 MLS. All Rights Reserved. The information provided is for clients' personal, non-commercial use and may not be used for any purpose other than to identify prospective properties clients may be interested in purchasing. All properties are subject to prior sale
or withdrawal.
Show More...
By registering, you agree to our Terms & Conditions
and that real estate professionals from Greater Baton Rouge and lenders may call/text you about your inquiry,
which may involve use of automated means and prerecorded/artificial voices. Message frequency varies.
Text HELP for help or STOP to cancel. You don't need to consent as a condition of buying any property,
goods or services. Messages/data rates may apply. Additional information about data use is in our
Privacy Policy.


text:
Outfit your business sales team with button down shirts that are perfect for your corporate look. IASpromotes.com's collection includes easy care, stain repellent styles in an exciting palette of colors that look great all day. Colleagues will be comfortable in any of the numerous fabrics these promotional button down shirts are made of as they carry out their daily activities.
Our custom button down shirts are available in both men's and women's styles. IASpromotes.com can help you choose the color and style that fits your image so that your expertly embroidered logo will clearly identify your representatives at marketing events.


text:
Find out more about Clarus' history, our mission and our philosophy in working with our clients.
Learn more about clients with whom we've worked and the benefits and savings they realized.
Find out more about the exciting changes going on at Clarus Communications
Meet the talented and experienced telecommunications consultants, ready to serve you.
We'll be a member of your team – sharing our expertise and making your priorities our own.
Clarus is affiliated with these telecom service companies, located in Cleveland, OH.
Our Master Agent Program allows our agents to earn aggressive commissions, while enjoying the full technical support of the Clarus team.
We put your service offering in our Quickie tool so other agents around the country can offer your products, helping your business grow.
We offer a wide range of telecommunications products and services, allowing our agents to be highly successful.
Get started, today, by reviewing and approving our agent agreement, allowing us to help you with your own telecommunications business.
We work with nationwide telecom providers to provide our clients with the best telecom options.
Clarus is proud to sell, service & support the best IP Phone Providers in the marketplace today.
We're a licensed agent for some of the largest Cloud Services Providers in the country.
We're proud to be licensed agents for some of the largest and most reliable wireless providers available.
We can offer your business cable television, nationwide, through our network of Cable TV Providers.
We strive hard to bring our clients the most complete suite of technology services, available.
We streamline Call Center operations
We know the Financial Services Industry
Innovative Solutions for Food Services
Universities rely on our expertise
Legal Professionals can rely on Clarus
We Excel in Multi-Location Installations
We help trucking companies connect
Clarus adds value to Entertainment
We're the right fit for gyms and spas
We help government run efficiently
We know the challenges in healthcare
Manufacturers rely on our expertise
Clarus helps connect the retail industry
We keep realtors connected everyday
Find out what's new in the industry, and what's new around Clarus, by following our Blog.
We have a number of technology white papers that might be of interest to prospective clients.
Learn more about Clarus by viewing our online customer and agent presentations.
We've collected a number of videos that will help you understand today's telecommunications landscape.
We've compiled some of the most frequently asked questions we receive, in order to serve you better.
Clarus is eager to serve you from any one of our regional offices
We're always on the lookout for top talent. Find out more about our career opportunities.
Subscribe to our Newsletter and keep up to date with the latest goings on at Clarus Communications
In order to make VoIP easy, we've produced a series of videos, which answer the most frequently asked questions. By watching these videos, we believe it will help you build a foundation of knowledge. These Telecom Videos will provide a brief explanation of each concept.
Download the Clarus Cloud Ebook
Fill out the form below and we will send the link to the email address provided.
We invite you to fill out the form, to the right, and someone from our offices will get back with you quickly.
We look forward to serving you.
We invite you to fill out the form below and someone from our offices will get back with you quickly.


text:
Buy Item Our Price$3.19 Retail:
Save 20% ($0.80)
In StockStock No: WW112751EB
WestBow Press / 2020 / ePub
Add To Cart
or checkout with
Add To Wishlist
Have questions about eBooks? Check out our eBook FAQs.
|Title: Beauty and Reflections for Your Catholic Journey: Filling Your Heart with the Holy Spirit - eBook
By: Elizabeth Pietrantonio
Format: DRM Free ePub
Vendor: WestBow Press
|Publication Date: 2020
Stock No: WW112751EB
What would you like to know about this product? Please enter your name, your email and your question regarding the product in the fields below, and we'll answer you in the next 24-48 hours.
If you need immediate assistance regarding this product or any other, please call 1-800-CHRISTIAN to speak directly with a customer service representative.


text:
Vintage Christian Dior eyewear, best known for their sleek frames, was first shown in the designer's Corolle collection in the late 1940s. It was said that this collection was dubbed the "New Look" of the era and helped reestablish Paris as the capital of the fashion world. Christian Dior frames made a huge statement at that time because of their new look. With the designer's niche for creating frames with various creative shapes, vintage Christian Dior eyewear became known for being unique from other designer eyewear at the time. Vintage Christian Dior sunglasses and frames are one of the most stylish and desirable glasses in the world today. Being one of the world's top fashion houses for decades, vintage Christian Dior eyewear was, and will always be classic statement pieces that will forever remain timeless. Here at the Vintage Frames Company, we have the most classic selection of vintage Christian Dior sunglasses and eyewear in the world! Check it out at the Vintage Frames Shop!
These Vintage Sunglasses are brand new DEADSTOCK. You will be receiving the exact ones you see in the picture, please make sure you check out the whole frame. Should you have any questions, please contact us for details. We have staff available 24hrs a day to help make your shopping experience as easy as possible!
- 150mm
- 17mm
- 62mm
- 56mm
- 135mm
Nous proposons une livraison express en 1 à 2 jours avec DHL. Vous pouvez retourner ou échanger vos lunettes dans les 7 jours suivant leur réception.
Politique complète d'expédition et de retour
authenticité VÉRIFIÉE


text:
If you have suffered a loss, we hope you can use these forum as a means of support to help you through.
August 8th, 2016, 11:27 PM
Trying to conceive but don't know where to start? Start here! For all your general questions and discussions on conception.
August 31st, 2016, 11:10 AM
If you have been trying to conceive for 12 months or more, this is the place to share stories and experiences with others in a similar situation.
August 18th, 2016, 09:11 AM
If you've been undergoing an Assisted Conception method for 12 months or longer, this forum is for sharing your experiences, thoughts and emotions during this time.
June 7th, 2016, 06:13 PM
Pregnancy buddies! Please join our due date groups at any time during your pregnancy.
Pregnancy general discussion, for all things pregnancy related! Share your questions and experiences here.
Pregnancy Symptoms By Week!...
August 19th, 2016, 01:00 AM
VBAC is a safe birth option - your scar is strong! If you are interested in a VBAC, HBAC, VBA2C or more, or if you've already had one, share your thoughts, feelings and experiences here.
April 25th, 2016, 10:41 AM
Giving birth soon? Have any questions about birth? Share your thoughts, opinions and issues about childbirth.
August 10th, 2016, 11:49 PM
Baby buddies! Do you have a baby or toddler (or several!) and are wanting to share your experiences with others who have little ones the same age as your own? Come and chat in our Baby Buddies groups!
Babies Born ~ September 2007...
August 31st, 2016, 07:54 AM
Have a baby or toddler in your home? Join in on our baby and toddler general discussion.
6/1/10 - Avasmum#1's little...
August 9th, 2016, 12:01 AM
Baby wearing is great for mums, dads and babies! If you enjoy wearing your baby or are interested in baby wearing, this forum is for you!
May 26th, 2015, 11:00 AM
Breastfeeding or bottlefeeding? No matter which way you feed your baby, if you need some advice or support, you can ask any questions here.
December 4th, 2019, 07:38 AM
Nappies or toilet training questions? Discuss all things nappies, from disposable to cloth, as well all your questions and experiences with toilet training.
June 9th, 2016, 06:27 PM
Parenting is so very rewarding, but it can also be tricky and patience testing! Share your experiences and advice here to help one another as parents, always learning on the job, as we go!
August 17th, 2016, 03:10 AM
No matter what size or shape your family comes in, feel free to share your experiences with others here.
December 12th, 2016, 11:40 AM
A forum to discuss your experiences and to ask questions about pre-school aged children from 2 to 5 years.
August 8th, 2016, 03:54 PM
A forum to discuss your experiences and to ask questions about school aged children and teenagers.
August 16th, 2016, 08:04 AM
A forum to discuss your experiences and questions on education, learning and childcare.
Parents Group - Gainsborough...
August 29th, 2016, 04:38 PM
This forum is an area to discuss what you do to expand your emotional health. What works for you? and What doesn't?
August 17th, 2016, 10:34 PM
For discussions such as weight loss, natural or alternative health and fitness, as well anything else relating to your well-being.
July 28th, 2016, 08:24 PM
This forum is for anything you might want to talk about but can't find a forum for! What did you get up to today? Got much planned on the weekend? Talk away...!
These forums are to discuss anything to do with your home and money. You might like to discuss buying or selling, home decorating, your garden, budgeting, money issues or anything to do with your house and home.
House Cleaners - How Much do...
August 27th, 2016, 07:54 PM
December 4th, 2019, 12:02 PM
For discussion about religion and spirituality.
June 17th, 2015, 10:00 AM
What are your hobbies and passions? Chat with others who have the same hobbies as yourself.
A forum for discussion on all things hobby related.
August 1st, 2016, 12:45 AM
Recipes, cooking and food. Like to cook? Like to eat? Then this is the place to be! Swap recipes here.
August 13th, 2016, 04:19 PM


text: Uncategorized October 2, 2019Hello world! Travel March 25, 2017Calm over the horizon ArtsBusiness March 22, 2017Inspired by clouds Business March 20, 2017Make it clean and simple Lifestyle March 18, 2017When you are alone Travel March 7, 2017Real time design tools LifestyleArts March 3, 2017Stumbled the concept Business March 2, 2017Time is passing by Travel February 18, 2017Hey DJ play that song Travel February 8, 2017Me Myself and I Arts February 6, 2017My tech travel setup Lifestyle February 2, 2017Learn the rules first LifestyleArts January 30, 2017The new brand identity Business January 28, 2017Sounds from the streets Lifestyle January 25, 2017A day alone at the sea Travel January 18, 2017Some amazing buildings ArtsBusiness January 14, 2017Working from your home? Business January 8, 2017Awwwards best websites


text:
The practice of dentistry encompasses an amazing array of services and procedures, all with a common goal: to help you to preserve your natural teeth as long as possible, ensure your oral health, and keep you looking and feeling great throughout life.
There's so much that can be done these days to improve the appearance of a person's smile — at any age. From powerful, professional whitening treatments to amazingly realistic porcelain veneers to state-of-the-art dental implants, there's a wide range of exciting possibilities.
The first step in any smile makeover is a thorough dental examination to make sure that your cosmetic problems really are just that, and not a sign of underlying dental disease. Once your health has been established, your smile can be cosmetically enhanced in a variety of ways.
General Dentistry Procedures
Modern dentistry offers a wide range of services to make sure your teeth stay healthy, function well and look great. These procedures include:
- Cleanings & Oral Exams, to keep your teeth and gums healthy, and catch early signs of dental disease
- Crowns & Bridgework, to replace large amounts of lost tooth structure and/or missing teeth
- Dental Implants, for the longest-lasting tooth replacement available today
- Extractions, to remove unhealthy teeth that cannot be saved
- Fillings, to restore decayed teeth
- Inlays & Onlays, to fill teeth with larger cavities
- Oral Cancer Screenings, to detect a dangerous disease that can be cured if caught early
- Orthodontic Treatment, to move teeth into the right position
- Removable Dentures, to help you smile again
- Root Canal Treatment, to rescue diseased teeth
- Sealants, to help prevent cavities
- Tooth-Colored Fillings, for a completely natural, healthy look
- Tooth Decay Prevention, so you keep your natural teeth as long as possible
When to Visit the Dentist
Many people only go to the dentist when something is wrong. That is truly a shame, because they are missing out on so many preventive services that can save discomfort — and expense — down the road. Regular dental visits are essential to make sure oral health problems — from tooth decay to oral cancer — are detected and treated in a timely manner. Some individuals may need to see the dentist more often than others to stay on top of problems like plaque buildup and gum disease, but everyone should go at least once per year.
Your regular dental visits will include a thorough oral exam to check the health of your teeth and gums; and oral cancer screening to spot any suspicious signs early; and a professional cleaning to remove stubborn deposits and make your teeth look and feel great. So don't miss out on the many benefits dentistry offers you and your family!
Your Smile Makeover
The most important job you have as a member of your own smile makeover team is to communicate exactly what you don't like about your smile and how you'd like it to be different. Before the first consultation, give some thought to the following questions:
- What do you like or dislike about the color, size, shape and spacing of your teeth?
- Are you pleased with how much your teeth show, both when you smile and when your lips are relaxed?
- Do you want teeth that are perfectly aligned and a bright "Hollywood White," or would you prefer a more natural look with slight color, shape and shade variations?
- Would you like more or less of your gums to show when you smile?
It is extremely helpful for you to bring in pictures you have collected — of smiles you like, smiles you don't like, and/or photos of the way your own smile used to look, if that's the result you're aiming for. Now is the time to get started on creating a smile that will make you feel as good as you look!
Related Articles
Tooth Decay — A Preventable Disease Tooth decay is the number one reason children and adults lose teeth during their lifetime. Yet many people don't realize that it is a preventable infection. This article explores the causes of tooth decay, its prevention, and the relationship to bacteria, sugars, and acids... Read Article
Cosmetic Dentistry — A Time For Change We are living in an exciting era in dentistry. Today more than ever before, the healing arts are able to provide cosmetic change to meet the public's ever-increasing expectations. Join Dear Doctor magazine as we review the myriad of possibilities available to you for cosmetic dental change... Read Article
Dentistry and Oral Health for Children Dear Doctor magazine brings you this wide-ranging overview of milestones and transitions in your child's dental development. Learn how to protect your children from tooth decay, dental injuries, and unhealthy habits while getting them started on the road to a lifetime of oral health and general well-being... Read Article


text:
These terms and conditions apply between you, the User of this Website (including any sub-domains, unless expressly excluded by their own terms and conditions), and Yates Brewery, the owner and operator of this Website. Please read these terms and conditions carefully, as they affect your legal rights. Your agreement to comply with and be bound by these terms and conditions is deemed to occur upon your first use of the Website. If you do not agree to be bound by these terms and conditions, you should stop using the Website immediately.
In these terms and conditions, User or Users means any third party that accesses the Website and is not either (i) employed by Yates Brewery and acting in the course of their employment or (ii) engaged as a consultant or otherwise providing services to Yates Brewery and accessing the Website in connection with the provision of such services.
You must be at least 18 years of age to use this Website. By using the Website and agreeing to these terms and conditions, you represent and warrant that you are at least 18 years of age.
Intellectual property and acceptable use
All Content included on the Website, unless uploaded by Users, is the property of Yates Brewery, our affiliates or other relevant third parties. In these terms and conditions, Content means any text, graphics, images, audio, video, software, data compilations, page layout, underlying code and software and any other form of information capable of being stored in a computer that appears on or forms part of this Website, including any such content uploaded by Users. By continuing to use the Website you acknowledge that such Content is protected by copyright, trademarks, database rights and other intellectual property rights. Nothing on this site shall be construed as granting, by implication, estoppel, or otherwise, any license or right to use any trademark, logo or service mark displayed on the site without the owner's prior written permission
You may, for your own personal, non-commercial use only, do the following:
retrieve, display and view the Content on a computer screen
You must not otherwise reproduce, modify, copy, distribute or use for commercial purposes any Content without the written permission of Yates Brewery.
Prohibited use
You may not use the Website for any of the following purposes:
in any way which causes, or may cause, damage to the Website or interferes with any other person's use or enjoyment of the Website;
in any way which is harmful, unlawful, illegal, abusive, harassing, threatening or otherwise objectionable or in breach of any applicable law, regulation, governmental order;
making, transmitting or storing electronic copies of Content protected by copyright without the permission of the owner.
Links to other websites
This Website may contain links to other sites. Unless expressly stated, these sites are not under the control of Yates Brewery or that of our affiliates.
We assume no responsibility for the content of such Websites and disclaim liability for any and all forms of loss or damage arising out of the use of them.
The inclusion of a link to another site on this Website does not imply any endorsement of the sites themselves or of those in control of them.
Cookies Policy
Use of the Website is also governed by our Cookies Policy, which is incorporated into these terms and conditions by this reference. View the Cookie Policy.
Availability of the Website and disclaimers
Any online facilities, tools, services or information that Yates Brewery makes available through the Website (the Service) is provided "as is" and on an "as available" basis. We give no warranty that the Service will be free of defects and/or faults. To the maximum extent permitted by the law, we provide no warranties (express or implied) of fitness for a particular purpose, accuracy of information, compatibility and satisfactory quality. Yates Brewery is under no obligation to update information on the Website.
Whilst Yates Brewery uses reasonable endeavours to ensure that the Website is secure and free of errors, viruses and other malware, we give no warranty or guaranty in that regard and all Users take responsibility for their own security, that of their personal details and their computers.
Yates Brewery accepts no liability for any disruption or non-availability of the Website.
Yates Brewery reserves the right to alter, suspend or discontinue any part (or the whole of) the Website including, but not limited to, any products and/or services available. These terms and conditions shall continue to apply to any modified version of the Website unless it is expressly stated otherwise.
Limitation of liability
Nothing in these terms and conditions will: (a) limit or exclude our or your liability for death or personal injury resulting from our or your negligence, as applicable; (b) limit or exclude our or your liability for fraud or fraudulent misrepresentation; or (c) limit or exclude any of our or your liabilities in any way that is not permitted under applicable law.
We will not be liable to you in respect of any losses arising out of events beyond our reasonable control.
To the maximum extent permitted by law, Yates Brewery accepts no liability for any of the following:
any business losses, such as loss of profits, income, revenue, anticipated savings, business, contracts, goodwill or commercial opportunities;
loss or corruption of any data, database or software;
any special, indirect or consequential loss or damage.
You may not transfer any of your rights under these terms and conditions to any other person. We may transfer our rights under these terms and conditions where we reasonably believe your rights will not be affected.
These terms and conditions may be varied by us from time to time. Such revised terms will apply to the Website from the date of publication. Users should check the terms and conditions regularly to ensure familiarity with the then current version.
These terms and conditions together with the Cookies Policy contain the whole agreement between the parties relating to its subject matter and supersede all prior discussions, arrangements or agreements that might have taken place in relation to the terms and conditions.
The Contracts (Rights of Third Parties) Act 1999 shall not apply to these terms and conditions and no third party will have any right to enforce or rely on any provision of these terms and conditions.
If any court or competent authority finds that any provision of these terms and conditions (or part of any provision) is invalid, illegal or unenforceable, that provision or part-provision will, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of these terms and conditions will not be affected.
Unless otherwise agreed, no delay, act or omission by a party in exercising any right or remedy will be deemed a waiver of that, or any other, right or remedy.
This Agreement shall be governed by and interpreted according to the law of England and Wales and all disputes arising under the Agreement (including non-contractual disputes or claims) shall be subject to the exclusive jurisdiction of the English and Welsh courts.
Yates Brewery of Unit 4 Langbridge Business Centre, Newchurch, Isle of Wight, PO36 0NP operates the Website https://yates-brewery.co.uk/.
Privacy Policy
By accepting these terms and conditions you also agree to the Privacy Policy of this website.


text:
This comic is currently unrated!
Got an opinion on this comedian's stand-up style?
Log-In or Register to rate this comic!
See the 25 Funniest Comedians
Influence the rankings by playing Who's Funnier.
"Analyzing humor is like dissecting a frog. Few people are interested and the frog dies of it."
—E. B. White
About | Terms of Service | Privacy Policy | Copyright 2004-2023 Todd Jackson


text:
▸▾ Claim This ListingReturn to Directory
You are not currently logged in. Please login or register first. When registering, you will receive an activation email. Be sure to check your spam if you don't see it in your email within 60 minutes.
Rosemont Property Management Company
Listed in Real Estate
523 E 11Th Str Duluth, MN
Long Business Description
Claim your listing to add a business description


text:
White Oak Presbyterian Church is a member of the ARP Synod. Founded in 1836, White Oak has been faithfully preserved by the Living God to be a faithful witness of the Gospel in this area. We are pleased to offer sermons on a new podcast system which is compatible with iPhones, iPads, and other popular mobile devices. Copies of the sermon are also available on CD upon request.
Apr 21, 2016
Sunday Morning Sermon with Pastor Tom Shoger
"The Four C's" - Hebrews 13:5-8
White Oak ARP is committed to glorifying God and enjoying Him forever. Toward this end, White Oak emphasizes meeting people's spiritual needs through accurate Biblical preaching and teaching from the Reformed perspective. To learn more about White Oak, please visit whiteoakarp.org.
Having trouble logging in?


text:
We offer private transfers from Aloha Beach Panglao at competitive, all inclusive prices.
Comfortable and Reliable transfers to Aloha Beach Panglao at fixed and affordable rates. Our prices include a licensed driver and vehicle, taxes and toll charges, luggage and extras such as child seats and ski equipment, waiting time and flight monitoring. Private tours, hire by the hour, van transfers, minibus and private coach transfers for large groups available on request. Lowest price guaranteed.
If you prefer driving, we now offer unbeatable rates for car rentals worldwide. A wide range of cars and minibus rentals from Aloha Beach Panglao are available to book online today.Book Now
If you are traveling to Aloha Beach Panglao from Tagbilaran, please visit
Tagbilaran transfers page.
For transfers from Aloha Beach Panglao to other destinations not listed please contact us.
We compare prices from the main transportation service providers in Aloha Beach Panglao to offer you the lowest rates.
Your connection to this website is secured using 256bit encryption and we do not store your sensitive information.
We don't believe in fake discounts. Our Aloha Beach Panglao Taxi prices are affordable and competitive.
This booking method is an alternative way to book your airport transfer from Aloha Beach Panglao
Please select a destination from the list below to set it as a drop-off point.


text:
Warning: Last items in stock!
The Tempo is a superb long haul, comfortable, spacious and fast.
The Tempo is a superb long haul, comfortable, spacious and fast. Well groomed and equipped with large storage compartments, it is really suitable for fitness practice, long walks, fishing and diving. available in pack. It's the kayak of the tall guys.
|450 cm
|34 cm
|24 kg
|Number of persons
|170 kg
|Purpose of usage
|Touring kayak
|Country of origin
* the delivery term of the goods may differ from the specified term, usually executed faster. In cases when the delivery time of the goods is extended due to unforeseen reasons, the seller undertakes to inform the buyer about the changes in the delivery time by the specified telephone and / or e-mail within the shortest possible time. The seller reserves the right to change the delivery terms by informing the buyer. The specified possible delivery times cannot be considered as obligations unless otherwise agreed.
** The product is currently out of stock, but we will have at specified date. PRE - ORDERS ACCEPTED. In some cases, changes to the delivery date are possible. If the expected date is changed, the date is also changed in the information notice of the product, and the buyers who have already ordered the product are informed by the telephone and / or e-mail specified by the buyer within the shortest possible time. The dates indicated are not an obligation of the seller to have the goods in stock at the specified time. The seller reserves the right to change these terms.
*** Initial delivery cost estimate is provided for one unit of goods delivered by courier in the territory of Lithuania. THIS IS INDICATIVE INFORMATION ONLY. The final delivery price may differ from the Initial delivery cost estimate depending on the type, quantity, delivery address and delivery method of the final order. The final delivery price of the product / goods can be seen only after the order is fully formed (by specifying the delivery address, choosing the delivery method).


text:
We can't find products matching the selection.
Adhering to its acclaimed Swiss watchmaking standards, Maurice Lacroix timepieces will make you yearn to wear them every hour of the day. With a driving focus on exceptional quality and the finest components, any choice you make from the World of Watches collections will demand their due in drawing attention while giving you a masterful collectible worthy of its heritage. Learn more about Maurice Lacroix.
was successfully added to your cart.
Shop By
Now Shopping by
- Product Category Watches Remove This Item
- Gender Womens Remove This Item
- Color White Remove This Item
- Dial Type Analog Remove This Item
Compare Products
You have no items to compare.